Project
Randomized phase III trial of Herceptin™ followed by Taxol plus Herceptin™ versus the combination of Herceptin™ and Taxol as palliative chemotherapy in patients with HER2-overexpressing advanced breast cancer
Automatically Closed · 1999 until 2015
Ruhstaller Thomas, Baumann Michael
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
1999
End Date
2015
Study Design
multicenter, prospective, non-blinded, randomized phase III trial
Keywords
Time to progression on combined HerTax,
Partner
Prof. Aron Goldhirsch, Milano
Dr. med. Olivia Pagani, Mendrisio
Brief description/objective
To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with weekly Tax (Arm A) vs. the upfront combination of both drugs (Arm B) in patients with ABC.